To retrospectively determine the accuracy of magnetic resonance (MR) imaging combined with MR cholangiopancreatography (CP) in differentiating benign from malignant intraductal papillary mucinous neoplasms (IPMNs) involving the main pancreatic duct (MPD), with histopathologic analysis as the reference standard.
I
ntraductal papillary mucinous neoplasms (IPMNs) of the pancreas originate from the mucinous epithelium of the pancreatic duct system and are characterized by papillary growth and hyperproduction of mucin, causing duct dilatation (1, 2) .
The gross appearance of these tumors depends on the site of origin along the pancreatic duct system: We can distinguish between IPMNs of the main pancreatic duct (MPD) (both those with segmental involvement and those with diffuse involvement), IPMNs of the side branches, and IPMNs of both the MPD and the side branches (mixed type) (3) . At histologic analysis, IPMNs are classified as adenomas, borderline tumors, or carcinomas depending on the degree of cytoarchitectural atypia (4, 5) .
Malignancy can occur as an in situ or invasive cancer in 30%-88% of IPMNs (6) . A stepwise progression from adenoma to carcinoma has been hypothesized because of the coexistence of different degrees of dysplasia in the same tumor (4, (7) (8) (9) . The risk of malignant degeneration correlates with the site of tumor origin: For MPD IPMNs, the mean risk is 70% (range, 57%-85%) (6, 7, 9, 10) ; however, for side branch IPMNs, the mean risk is 25% (range, 6%-46%) (9, (11) (12) (13) (14) (15) . It is assumed that the risk of malignant degeneration of mixed type IPMNs is similar to that of MPD IPMNs; however, to our knowledge, there are no published findings to confirm this likely hypothesis. Because of this different biologic behavior and prognosis, surgery is indicated in patients with IPMNs involving the MPD (7, 16, 17) ; therefore, preoperative characterization of IPMNs as adenomas, borderline tumors, or carcinomas is needed to properly select candidates for surgical procedures and help the surgeon plan the timing, type, and extent of resection.
There are clinical parameters-such as recent onset of jaundice, diabetes, weight loss, and abdominal pain-and tumor markers-such as carcinoembryonic antigen and Ca19-9 levels-that may help to predict malignancy. However, these cannot be used to reliably distinguish benign IPMNs from malignant IPMNs involving the MPD because they widely overlap (7, 18) . For this reason, imaging criteria have been proposed for use in lesion characterization. These include MPD caliber of at least 15 mm, diffuse dilatation of the MPD, mural-based nodules, and contrast enhancement of the duct wall. These features have been reported in series that grouped MPD IPMNs, mixed type IPMNs, and side branch IPMNs (11, (19) (20) (21) .
Magnetic resonance (MR) imaging is potentially the most accurate imaging method used to depict these signs because it can be used to simultaneously investigate pancreatic parenchyma with cross-sectional imaging and the pancreatic duct system with MR cholangiopancreatography (CP) (19, 22) .
The primary objective of our study was to retrospectively determine the accuracy of MR imaging combined with MR CP in differentiating benign from malignant IPMNs involving the MPD, with histopathologic analysis as the reference stnadard. The secondary objective was to compare the biologic behavior and prognosis of MPD and mixed type IPMNs.
Materials and Methods

Patient Population
This retrospective study was approved by our investigational review board, and the requirement for informed consent 
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Advances in Knowledge
The clinical findings and laboratory data of the patient population at the time of diagnosis are summarized in Table E1 (Table E1 [online]). Of note, five (10%) of 51 patients were asymptomatic, and the diagnosis of MPD IPMN was made at diagnostic imaging performed for other reasons.
All patients underwent MR imaging, MR CP, and a surgical procedure. The mean interval between (a) MR imaging and MR CP and (b) surgery was 2.6 months (range, 1 day to 20 months). Surgery was indicated by clinical signs and symptoms, laboratory data that were indicative of malignancy, and imaging findings. At surgery, 27 (53%) of the 51 patients underwent pancreaticoduodenectomy; 17 (33%), distal pancreatectomy; and seven (14%), total pancreatectomy. The type of resection was determined according to the site of the tumor, as indicated by preoperative examination findings, and the extent of surgical resection was determined according to the results of frozen section examination of the cut surface during the surgical procedure (23) . The median follow-up time was 29.5 months (mean, 36 months; range, 4 -127 months).
MR Imaging
MR imaging was performed with a 1.5-T imager (Magnetom Symphony; Siemens, Erlangen, Germany) and use of a four-channel phased-array coil. The patients were asked to fast for 4 -6 hours before the examination. Furthermore, to eliminate overlapping fluid-containing organs on T2-weighted images, a negative contrast agent was administered before MR imaging. This consisted of administration of 50 -150 mL of superparamagnetic iron oxide particles (ferumoxsil, Lumirem; Guerbet, Aulnay-sous-Bois, France) 10 -20 minutes before the start of the examination. No antiperistaltic drug was administered.
The MR protocol included the following elements (Table 1) : A chemicalshift T1-weighted gradient-echo sequence was performed with in-and out-of-phase echo times in the axial plane, a fat-saturated T2-weighted RARE sequence was performed in the axial plane, and a T2-weighted half-Fourier RARE sequence was performed in the coronal and axial planes.
Sagittal and coronal oblique halfFourier RARE sequences with appropriate angulation (mean, 6; range, 3-10) to depict the longest diameter of the pancreatic duct were performed to optimize depiction of the pancreatic duct system.
Once the most appropriate plane in which to assess the biliopancreatic duct system was identified, MR CP was performed in all patients with a two-dimensional half-Fourier RARE heavily T2-weighted pulse sequence during breath holding along the most appropriate coronal or coronal oblique plane to best depict the pancreatic duct system, the biliary tree, both papillae, and the duodenum.
In addition, in 19 (37%) of the 51 patients, respiratory-triggered threedimensional half-Fourier RARE MR CP was also performed along the coronal oblique plane. The respiratory-triggered three-dimensional half-Fourier RARE source images were analyzed and postprocessed with a maximum intensity projection algorithm at a workstation.
Dynamic imaging during gadolinium chelate injection was performed with a three-dimensional volumetric gradientecho pulse sequence (referred to as the volumetric interpolated breath-hold examination) with fat saturation along the axial plane and use of parallel imaging (generalized autocalibrating partially parallel acquisition acceleration factor, 2). A quadriphasic dynamic examination was performed during injection of 0.1 mmol per kilogram of body weight gadolinium Qualitative image analysis included assessment of the following parameters: site of dilatation of the MPD (dilatation of the head, body, and/or tail of the pancreas or diffuse dilatation), presence or absence of duct wall nodules (endoluminal filling defects adjacent to the nondependent duct wall seen on either T2-weighted MR images or postcontrast fat-suppressed T1-weighted MR images), and signal intensity enhancement of the MPD walls on postcontrast fat-saturated T1-weighted MR images compared with that on precontrast MR images. Endoluminal filling defects adjacent to the dependant wall of the MPD were not considered for image analysis because of the difficult differential diagnosis between mucin or protein plugs and duct wall nodules.
Quantitative image analysis included measurement of the maximum diameter of the MPD and the maximum diameter of the MPD wall nodules. We considered the upper limits of MPD diameter to be 5, 4, and 3 mm in the head, body, and tail of the pancreas, respectively (24) . The MR and MR CP findings were subsequently compared with the histopathologic data.
Histopathologic Analysis
The pancreatic specimens were dissected along the MPD and then fixed in a 10% formaldehyde solution. The entire portion of the resected pancreas was included and examined with a light microscope.
The histopathologic type and extent of the intraductal papillary mucinous pancreatic tumor, the involvement of the MPD, and the histopathologic status of the final pancreatic cut surface were systematically assessed by a pathologist (P.C., 18 years of experience).
At histopathologic analysis, epithelial lesions of the MPD IPMNs were classified into three histopathologic subtypes-adenoma, borderline tumor, and adenocarcinoma-according to the World Health Organization classification system (5, 9) . The correlation between clinical presentation and histopathologic features is reported in Table E1 (Table  E1 [online]). Subsequently, histopathologic and gross morphologic findings in the surgical specimen were compared with the imaging findings by a pathologist (P.C.) and a radiologist (M.M.). The histopathologic examination was the reference standard in this study. For data analysis, benign and borderline tumors were grouped together as benign tumors. The comparison between subgroups, which were identified by status at histopathologic diagnosis (adenoma, borderline tumor, or carcinoma), was performed with the Student t test (patient age) and the Mann-Whitney U test (diameter of the MPD) for continuous variables. Qualitative data were compared with the 2 or Fisher exact tests, when necessary. In 51 patients who underwent resection, multivariate analysis was performed with the binary logistic regression model to evaluate the relative role of the MR imaging parameters in predicting malignancy. Survival was defined as the time from surgical resection to death and was considered the last follow-up date if no events had occurred. Survival probability was estimated with the KaplanMeier method, whereas the log-rank test was used for univariate survival analysis in different subgroups. P Ͻ .05 was considered indicative of a significant difference.
Statistical Analyses
Results
At histopathologic examination of the surgical specimen, 27 (53%) of the 51 IPMNs were classified as carcinomas, 13 (25%) were classified as borderline tumors, and 11 (22%) were classified as adenomas involving the MPD. Of the 51 IPMNs, 29 (57%) involved only the MPD, whereas the remaining 22 (43%) also involved the side branches (mixed type). A further analysis of the histopathologic features of the IPMNs is reported in Tables E1 and E2 (Tables 
Qualitative Image Analysis
Site of ductal dilatation.-Dilatation of the MPD was diffuse in 30 (59%) of the 51 patients (Fig 1) localized to the body or tail of the pancreas in 15 (29%) patients, and localized to the head of the pancreas in six (12%) patients (Figs 1, 2) . The interobserver agreement in assessing the site of ductal dilatation was good ( ϭ 0.689).
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Of the 27 patients with intraductal papillary mucinous carcinomas, 20 (74%) had diffuse dilatation of the MPD (Fig 1) , six (22%) had localized dilatation of the body or tail of the pancreas (Fig 2) , and one (4%) had localized dilatation of the head of the pancreas ( Table 2) . Of the 24 patients with a histopathologic diagnosis of intraductal papillary mucinous adenoma or borderline neoplasm, 10 (42%) had diffuse dilatation of the MPD, nine (38%) had dilatation of the MPD localized to the body or tail of the pancreas, and five (21%) had dilatation of the MPD localized to the head of the pancreas (Table 2 ). Further data on the site of ductal dilatation in the group of patients with malignant tu- Table 2 . MPD wall nodules adjacent to the nondependant wall of the MPD were observed in 17 (33%) of 51 patients with IPMN involving the MPD (Fig 3) . There was moderate interobserver agreement when assessing the presence or absence of MPD nodules ( ϭ 0.509).
Sixteen (59%) of 27 intraductal papillary mucinous carcinomas involving the MPD had mural nodules (Table 2, Fig 3) . One (4%) of the 24 patients with an intraductal papillary mucinous adenoma or borderline tumor had MPD wall nodules (Table 2, Fig 3) .
Enhancement of the MPD walls.-Duct wall enhancement was observed in 25 (49%) of 51 patients with IPMN involving the MPD (Fig 4) . There was good interobserver agreement in assessing enhancement of the MPD walls ( ϭ 0.687).
In the group of 27 patients with intraductal papillary mucinous carcinoma involving the MPD, 20 (74%) patients had duct wall enhancement, whereas in the group of 24 patients with intraductal papillary mucinous adenoma or borderline neoplasm, five (21%) patients had MPD wall enhancement (Table 2, Fig 4) . The results of a subanalysis of the MPD wall enhancement in the patients with malignant tumors and adenoma or borderline tumors are reported in Table 2 .
Quantitative Analysis
The median maximal diameter of the MPD was 14 mm (interquartile range, 9 -26 mm; mean, 25 mm; range, 10 -180 mm) (Fig 1) . The median maximal diameter of the MPD of malignant IPMNs was 18 mm (interquartile range, 10 -35 mm; mean, 34 mm; range, 7-180 mm), 
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Manfredi et al whereas that of benign lesions was 11 mm (interquartile range, 7.3-19 mm; mean, 15 mm; range, 4 -40 mm) (P ϭ .038) ( Table 2 ). The mean maximal diameter of the MPD wall nodules was 10.2 mm (range, 3-21 mm). By applying univariate statistical analysis to these parameters, the presence of parietal nodules was significantly correlated with malignancy (P Ͻ .00001) ( Table 2) . Also, the finding of duct wall enhancement was correlated with a diagnosis of malignant IPMN (P ϭ .0001) ( Table 2 ). The site of dilatation was not indicative of the biologic behavior of the IPMNs (P ϭ .169). However, patients with segmental dilatation of the MPD (head, body, or tail of the pancreas) had a lower probability of having a malignant IPMN (seven [33%] of 21 patients) than did patients with diffuse MPD dilatations (20 [67%] of 30 patients).
In the logistic model we developedwhich considered the potential confounders of age, sex, lesion type (MPD or mixed), and site of MPD dilatationthe presence of mural nodules and/or enhancement of the duct walls (relative risk, 3.2; 95% confidence interval: 1.05, 9.78; P ϭ .031) were significant predictors of malignant IPMNs (relative risk, 4.48; 95% confidence interval: 1.61, 12.44; P ϭ .0016) (Table E2 [online]).
Cumulative patient survival according to the type of IMPN (MPD vs mixed) is reported in Figure 5 .
Discussion
In our study, we analyzed the predictive signs of malignancy, as determined with MR imaging and MR cholangiopancreatography, for MPD and mixed type IPMNs because their prognosis is different from that of side branch IPMNs. The risk of malignant transformation for IPMNs involving the MPD is 30%-60% (6,7,9,10), whereas it is 6%-46% (11-15) for side branch IPMNs. In our study, the most accurate sign of malignancy was the depiction of MPD mural nodules, which were seen in 16 (59%) of 27 patients with malignant IPMNs and in one (4%) of 24 patients with adenomas or borderline IPMNs (P Ͻ .00001) (this lesion was detected in a borderline IPMN), with associated enhancement of the duct walls. None of the patients with intraductal papillary mucinous adenomas had mural nodules. These results are in agreement with the published findings of other studies in which researchers analyzed both MPD and side branch IPMNs together (3, 11, 13, 19, 22, 25, 26) . The challenge for the radiologist in these cases is to identify the nodules when they are small (mean maximal diameter, 10.2 mm in our study) in order to diagnose malignant disease early in its course. This may be a difficult task, and it is most likely responsible for the moderate interobserver agreement on detection of this sign in our series. Therefore, it is important to obtain three-dimensional high-spatial-resolution images during the dynamic study. It has been shown that mural nodules may also be depicted with computed tomography (CT), particularly when two-dimensional curved reformations are obtained. These reported CT results show diagnostic accuracy is comparable with that reported with MR imaging and MR CP (27) . This is important because CT is frequently the modality of choice in the assessment of patients known to have or suspected of having pancreatic disease.
According to the literature (11, (19) (20) (21) , contrast enhancement of the MPD walls is another sign that is predictive of malignancy; however, it is more difficult to depict than parietal nodules because it requires a point-by-point comparison between the pre-and delayed postcontrast images. However, in our series, contrast enhancement of the MPD duct walls was less reliable than the presence of parietal nodules when predicting malignant transformation because it was depicted in 20 (74%) of 27 patients with malignant MPD or mixed type IPMNs and in five (21%) of 24 patients with benign or borderline IPMNs. This indicates that this sign could be caused by malignant transformation and inflammatory changes, which are frequently noted in the upstream MPD in patients with IPMNs. However, the multivariate analysis performed in our study indicated that the relative risk of malignancy was increased by a margin of 4.48 when mural nodules and enhancement of the duct wall were present simultaneously.
We found that the site of the dilatation was not a significant predictor of malignancy. This result was in agreement with the findings of other published series (7, 21) . However, diffuse dilatation of the MPD is detected more frequently in patients with malignant IPMNs involving the MPD. This finding most likely indicates the presence of a 
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Our results concerning the predictive value of the size of the MPD are in agreement with those of other published reports (11) , indicating that malignant IPMNs had a larger median maximal diameter of the MPD (18 mm) than did benign or borderline IPMNs of the MPD (11 mm) (P ϭ .038). To assess the pancreatic duct system, Carbognin et al (28) suggested that the use of a three-dimensional MR CP sequence in conjunction with the administration of secretin was helpful in depicting the communication between side branch IPMNs and the MPD. In case of MPD IPMNs, the medical need is to characterize the lesions by depicting mural nodules. In this setting, three-dimensional MR CP, which is a respiratory-triggered pulse sequence, may be limited by some blurring due to respiratory artifacts.
In pursuing the secondary objective of our study, we found that the 5-year survival rate of patients with IPMNs involving only the MPD are not significantly different from those of patients with mixed type IPMNs (P ϭ .813). This suggests that the biologic behaviors of the two types of IPMNs are similar; therefore, patients with MPD IPMNs and those with mixed type IPMNs are candidates for surgery.
Our study had some limitations. First, the patients included in this study were taken from a select group of patients with IPMNs because they had undergone MR imaging, MR CP, and surgery; therefore, our data contain the so-called verification or work-up bias (29) that may be partially responsible for some overestimation of the frequency of the reported signs that are indicative of malignancy. For the same reason, our data are insufficient to evaluate the actual prevalence of the disease. Other limitations are the minor differences in the imaging protocol sequences and parameters, the rate of contrast agent injection, and the timing of the dynamic study (fixed time delays, automated scanning trigger software, or test bolus) due to the retrospective nature of our study.
In conclusion, our data suggest that MR imaging and MR CP may be used to identify signs, such as mural nodules along the walls of the MPD and duct wall enhancement, that are predictive of malignancy. The identification of these signs in IPMNs involving the MPD, in combination with clinical symptoms and laboratory data, should help the surgeon choose the timing and type of surgical procedure to be performed in these patients. This surgical procedure represents the only curative treatment.
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